Markets:

Overview

News

Currencies

International

Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.200 -0.030 (-2.44%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Coherus BioSciences's Earnings Outlook ↗

November 05, 2025

Via Benzinga

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗

October 10, 2025

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.

Via Benzinga

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

September 04, 2025

Via Benzinga

Coherus (CHRS) Q2 Revenue Jumps 10% ↗

August 07, 2025

Via The Motley Fool

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Insights Ahead: Coherus BioSciences's Quarterly Earnings ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

Earnings Preview: Coherus BioSciences ↗

May 09, 2025

Via Benzinga

Recap: Coherus BioSciences Q4 Earnings ↗

March 13, 2024

Via Benzinga

Which stocks are moving after the closing bell on Friday? ↗

July 04, 2025

The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 03, 2025

Via Benzinga

Top movers in Friday's after hours session ↗

May 23, 2025

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Earnings Preview For Coherus BioSciences ↗

March 12, 2024

Via Benzinga

Which stocks are moving before the opening bell on Tuesday? ↗

May 13, 2025

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 13, 2025

Via Benzinga

Which stocks are moving after the closing bell on Wednesday? ↗

April 16, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Earnings Scheduled For March 10, 2025 ↗

March 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 03, 2024

Via Benzinga

Why Is Coherus BioSciences Stock Trading Higher On Tuesday? ↗

December 03, 2024

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 07, 2024

Via Benzinga

CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary ↗

June 30, 2024

Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to...

Via Talk Markets

CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Why Coherus Biosciences Stock Tumbled on Thursday ↗

March 14, 2024

The company fell well short of expectations for its fourth quarter.

Via The Motley Fool

Earnings Scheduled For March 13, 2024 ↗

March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.

Via Benzinga

Why Coherus BioSciences Stock Jumped Today ↗

February 06, 2024

As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.

Via The Motley Fool

Why Coherus BioSciences Stock Is Sinking Today ↗

January 23, 2024

The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.

Via The Motley Fool

Why Coherus Biosciences Popped Today ↗

January 22, 2024

Coherus is divesting its non-core ophthalmology franchise.

Via The Motley Fool

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 22, 2024

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Search Hotels in Sausalito

Find A Business

or Browse Listings

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

Headline News about Coherus Oncology, Inc. - Common Stock